Routes of Metastatic Spread
Malignant neoplasms can disseminate throughout the body via several routes, frequently involving multiple pathways simultaneously or sequentially.
- Direct extension (contiguous spread): A tumor cell makes direct contact with unaffected tissue. A classic example is gastric cancer invading the peritoneum or lung cancer invading the pleura.
- Implantation (transcoelomic) spread: Tumor cells are disseminated via body fluids (cerebrospinal fluid, exudate). This typically occurs within serous cavities (pleural, peritoneal) or along the meninges of the brain and spinal cord.
Stages of Vascular Metastasis
The transport of cells via blood and lymphatic vessels involves four distinct stages:
- Detachment and intravasation: A malignant cell detaches from the primary tumor, invades the wall of a microvessel, and enters its lumen.
- Embolism: The cell circulates in the blood or lymph and subsequently adheres (adhesion phase) to the vascular endothelium at a new site.
- Extravasation: The tumor cell breaches the vessel wall from within and migrates into the surrounding healthy tissue.
- Metastatic colonization: The tumor cells actively proliferate to form a secondary nodule identical to the primary tumor.
Organ Selectivity (Tropism)
Metastases do not spread randomly; they exhibit 'address specificity,' showing a propensity to target specific organs. For instance, lung cancer frequently metastasizes to bones, the liver, and the brain, whereas gastric cancer metastasizes to the pelvic floor and ovaries (known as a Krukenberg tumor).
This selectivity depends on several factors:
- Metabolic conditions: The metabolic profile of the target organ must be favorable for the specific tumor.
- Anatomic pathways: Local blood flow and lymphatic drainage patterns.
- Compromised local immunity: Low efficacy of antitumor resistance mechanisms within the tissue.
- Positive chemotaxis: Chemical attraction of malignant cells.
Epithelial-Mesenchymal Transition (EMT)
EMT plays a critical role in metastatic potential. During this process, cells activate embryonic genes, enabling them to become actively migratory.
For example, in melanoma, cell-cell adhesion protein expression is switched: E-cadherin (responsible for connections with the epithelium and keratinocytes) is replaced by N-cadherin (mediating contact with mesenchymal cells). As a result, melanocytes lose attachment to their microenvironment, begin interacting with epidermal growth factor, and purposefully migrate toward vessel walls.
Tumor Progression and Recurrence
Tumor progression is an irreversible, genetically fixed alteration of cellular properties that is heritable (a phenomenon first described by L. Foulds in 1969). Due to high genotypic variability, the tumor becomes heterogeneous. Different cell clones emerge, allowing the neoplasm to adapt to hypoxia, nutrient deprivation, or pharmacological agents (treatment escape phenomenon). The ultimate outcome of progression is an increase in atypia and malignancy.
Recurrence is a classic growth pattern where a tumor redevelops at the primary site following surgical resection. The causes stem either from residual viable cells (due to incomplete excision or early invasion) or from the genetic transformation of adjacent normal cells. According to this hypothesis, DNA fragments containing oncogenes from lysed tumor cells can integrate into the genome of healthy cells.